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Abstract Ocular toxoplasmosis, which is caused by the
protozoan parasite Toxoplasma gondii, is the leading cause of
retinochoroiditis. Toxoplasma is an obligate intracellular
pathogen that replicates within a parasitophorous vacuole.
Infections are initiated by digestion of parasites deposited in
cat feces or in undercooked meat. Parasites then disseminate
to target tissues that include the retina where they then
develop into long-lived asymptomatic tissue cysts. Occasion-
ally, cysts reactivate and growth of newly emerged parasites
must be controlled by the host’s immune system or disease
will occur. The mechanisms by which Toxoplasma grows
within its host cell, encysts, and interacts with the host’s
immune system are important questions. Here, we will discuss
how the use of DNA microarrays in transcriptional profiling,
genotyping, and epigenetic experiments has impacted our
understanding of these processes. Finally, we will discuss how
these advances relate to ocular toxoplasmosis and how future
research on ocular toxoplasmosis can benefit from DNA
microarrays.
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Introduction
Toxoplasma gondii is an obligate intracellular Apicom-
plexan parasite that can infect a wide range of warm-
blooded animals including humans [1]. This pathogen is
one of the most common in humans due to many
contributing factors that include: (1) its complex life cycle
allows it to be transmitted both sexually via felid fecal
matter and asexually via carnivorism. (2) Toxoplasma has
an extremely wide host cell tropism that includes most
nucleated cells. (3) In humans and other intermediate hosts,
Toxoplasma develops into a chronic infection that cannot be
eliminated by the host’s immune response or by currently
used drugs. In most cases, chronic infections are largely
asymptomatic unless the host becomes immune compro-
mised. Together, these and other properties have allowed
Toxoplasma to achieve infection rates that range from
~23% in the USA [2] to 50–70% in France [3, 4].
In humans and other intermediate hosts, infections are
the result of digesting parasites shed in felid feces or
present in undercooked meat [4]. Both infection routes
result in the infection of intestinal cells after which the
parasites develop into tachyzoites, which are the fast-
growing, disseminating form of the parasite. Tachyzoites
replicate within intestinal cells where they stimulate
recruitment of neutrophils and dendritic cells. The parasite
can then infect these immune cells and use them to
disseminate throughout their hosts [5, 6]. Once parasite
reach their target tissue they respond to the resulting IFNγ-
based Th1 response by transforming into bradyzoites.
Ultimately, bradyzoites will form quiescent tissue cysts that
do not cause any significant disease [7]. Bradyzoite
conversion is a critical step in the parasite’s life cycle since
bradyzoites are impervious to immune-mediated destruc-
tion, are relatively non-immunogenic, and are the infectious
form of the parasite during horizontal transmission (e.g.
digestion of undercooked meat). Thus, it is critical that
tachyzoites evade IFNγ-induced death while they convert
to bradyzoites. The molecular details underlying each of
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these processes are largely unknown but are important
because these data could lead to the development of new
drugs to treat the infection.
The past decade has seen important developments in the
molecular tools to study Toxoplasma gondii. These include
the development of transfection technologies [8–10],
sequencing of both host and parasite genomes (see www.
toxodb.org), increasing use and refinement of high-
throughput genomic and proteomic technologies [11–17],
sensitive whole animal imaging [18–20], and large-scale
mutagenesis-based screens [21, 22]. These technologies and
approaches have been instrumental in increasing our under-
standing of Toxoplasma replication within its host cell,
bradyzoite development, and virulence mechanisms. In this
review, we will focus our discussion on how the use of DNA
microarrays and other high-throughput transcriptome analysis
contributed to these developments and the implications these
findings have for ocular disease.
The role of host cell transcription in Toxoplasma gondii
growth
A common requirement for intracellular pathogens is they
must scavenge nutrients from their hosts while avoiding
innate host defense mechanisms [23]. Toxoplasma is no
different and how it replicates within a host cell has been the
focus of intense investigation by several laboratories.
Biochemical- and cell-biological-based assays demonstrated
that parasites modify host microtubule and intermediate
filament organization [24–26], inhibit host cell apoptosis [27,
28], upregulate pro-inflammatory cytokines [29–32], and
scavenge purine nucleosides, cholesterol, and other nutrients
from their host cells [33, 34].
To examine the molecular basis for these changes, we
and others used DNA microarrays to analyze changes in
host gene expression following infection [11, 17, 35].
These studies indicated that changes in host transcription
were extremely widespread. These changes came in at least
two distinct waves with the first wave being induced within
2 hours and included a large number of pro-inflammatory
response genes [11]. The significance of the expression of
these genes will be discussed later in this review. Besides
the inflammatory response genes, the first wave of gene
expression also included genes (EGR1, EGR2, c-jun, and
jun-B) that encode transcription factors commonly activated
in response to cellular stresses. These data suggests that
activation of these genes helps the infected host cell
withstand the stress of a Toxoplasma infection. In support
of this hypothesis, upregulation of these genes is not a
general feature of a cell’s response to infection since these
genes were not modulated in host cells infected with either
Trypanosoma cruzi [36] or the closely related Apicom-
plexan parasite, Neospora caninum [37]. This result
indicated that parasite activation of these transcription
factors is accomplished through a Toxoplasma-derived
molecule that interacts with a specific host protein. One
mechanism by which Toxoplasma can specifically signal to
its host cell is by the release of proteins from the rhoptries,
which are specialized secretory organelles that contain
proteins secreted into the host cytoplasm and nucleus, in a
manner analogous to bacterial Type III secretion systems
[38]. Consistent with rhoptries being key regulators of host
cell functions, upregulation of EGR2 and, likely the other
immediate early response host transcription factors, is
mediated by a rhoptry factor [37].
The second wave of gene expression included genes that
encode proteins that function in a diverse set of cellular
processes. Most striking from these studies was the finding
that glucose, mevalonate, and iron metabolic genes were
upregulated specifically by Toxoplasma [11]. This was
intriguing because these genes function in pathways related
to some of Toxoplasma’s auxotrophies. Thus, their upregu-
lation may be necessary to increase levels these nutrients
for the parasite to scavenge. Expression of the glycolytic
and iron genes (as well as other genes also observed in the
microarray experiments) is regulated by a common tran-
scription factor named hypoxia inducible factor 1 (HIF1)
[39, 40]. HIF1 is a heterodimer composed of α and β
subunits and stabilization of HIF1α is the rate-limiting step
to its activation. Consistent with the array data, Toxoplasma
increased HIF1α proteins levels, activated HIF1-dependent
transcription, and required HIF1α for parasite growth [41].
Host cell cycle modulation is a common cellular target
for many types of pathogens [42]. When both proliferating
and non-proliferating cells are infected with Toxoplasma,
genes commonly associated with cell growth are differen-
tially modulated [11, 43]. These data suggested that like
other intracellular pathogens, Toxoplasma is actively
modulating the host’s cell cycle. This hypothesis was
tested by several groups who demonstrated that parasite
infection leads to changes in host cell cycle progression
and causes cells to arrest at the G2/M border [16, 44, 45].
Toxoplasma’s effect on the host cell cycle was cell type
independent, which was consistent with the microarray
data noting differential expression of these genes in
various types of infected host cells. Surprisingly, both
replicating and senescent cells were similarly affected. The
specific parasite factor(s) that regulate the host cell cycle is
unknown but at least one appears to be a secreted factor larger
than 10 kDa [45]. The importance of such an extrinsic-acting
factor is unknown but could be to optimize neighboring cells
for infection.
Besides regulating expression of metabolic and cell
cycle genes, anti-apoptotic transcripts are a third major
class of genes upregulated in Toxoplasma-infected cells.
Given that apoptosis of cells infected with viruses and
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bacteria is one host defense against infection [46, 47], it is
logical that Toxoplasma would actively prevent host cell
apoptosis and appears to do so by interfering with both
extrinsic and intrinsic induction of apoptosis (reviewed in
[48]). The extrinsic pathway is activated by death signals
such as TNFα and FAS and is dependent on Caspase 8.
Toxoplasma interferes with this process by blocking
Caspase 8 activity [49]. In contrast, parasite modulation of
the intrinsic pathway, which is activated by intracellular
stress and the subsequent release of cytochrome C from the
mitochondrion, is dependent on the host cell transcription
factor NF-κB [50]. NF-κB is a family of five different
proteins and several of these have been observed to be
activated in parasite-infected host cells [51–53]. The NF-
κB-regulated genes required for parasite inhibition of host
cell apoptosis are unknown but candidates include the anti-
apoptotic gene bcl2 as well as several members of the IAP
family.
Turning on and off the switches that regulate bradyzoite
development
Bradyzoite development is a complex process in which the
parasite expresses enzymes that allow it to form a cyst wall
while dramatically altering its metabolism and immunological
characteristics [7]. These changes are important because
bradyzoite-containing cysts are impervious to host defenses
and currently prescribed anti-toxoplasmotic drugs. In addition,
bradyzoite differentiation is a critical step in the parasite’s life
cycle since cysts are a transmissible form of the parasite
during horizontal transfer. Molecular characterization of the
genes encoding bradyzoite-specific antigens indicated that
their stage-specific expression was due, in large part, to
increasing the abundance of the transcripts that encode them
[54–56]. It was not until the transcriptomes of bradyzoites and
tachyzoites were directly compared by either comparative
EST sequencing or SAGE analysis that the extent of these
changes were realized [57, 58]. Although these studies were
critical in allowing us to appreciate the complexity of the
transcriptional changes that take place during development,
the laborious nature of preparing and analyzing EST and
SAGE libraries limited their ability to assess the dynamic
nature of bradyzoite development.
In contrast, an important advantage of DNA microarrays
is that they can readily examine multiple time points and
conditions [59]. As a first step, microarrays spotted with the
cDNAs used for the bradyzoite EST sequencing project
[58] were generated and used to compare the transcriptional
responses that take place at various time points following
induction of differentiation [13]. Although these first
generation microarrays were spotted with fewer than 650
unique genes, they demonstrated that the microarrays could
be used to discover additional bradyzoite-specific genes.
Besides gene discovery, DNA microarrays can also be used
to map transcriptional pathways. As an example, the
transcriptional response of wild-type parasites and brady-
zoite differentiation mutants were compared after stimulat-
ing the parasites to undergo differentiation. The resulting
microarray data demonstrated that the transcriptional path-
ways induced during development were hierarchal [60, 61].
The full complexity associated with differentiation was
demonstrated using full-genome Toxoplasma microarrays
that compared the transcriptional responses of three distinct
Toxoplasma strains to a drug that induces bradyzoite
development [62]. Analysis of the 5’ proximal promoters
of some bradyzoite-specific genes identified a short 6–8 bp
sequence that conferred stage-specific expression. Electro-
phoretic mobility shift assays indicated that a parasite
nuclear factor binds this promoter element [62]. This was a
significant finding because Toxoplasma’s genome (and
those of other Apicomplexan parasites) lacked genes that
shared homology with most known transcription factors.
Recently, however, a novel transcription factor family
(ApiAP2) was identified in Plasmodium falciparum [63]
and subsequent sequence analysis indicated that Toxoplas-
ma’s genome possesses approximately 40 ApiAP2 family
members [64]. Given the lack of other known transcription
factors and the large number ApiAP2 proteins, it is likely
that one or more members of this family will be involved in
bradyzoite development.
Post-translational modifications of histones (e.g. acety-
lation and methylation) are a widespread epigenetic
mechanism critical for regulating gene expression [65].
Due to a lack of experimentally confirmed bradyzoite-
inducing transcription factors, investigators began testing
whether bradyzoite-specific gene expression could be
regulated by epigenetic remodeling. These experiments
demonstrated that the promoters of bradyzoite-specific
genes in parasites growing under tachyzoite conditions
have low levels of acetylated histones and become more
extensively modified after exposure to bradyzoite-inducing
conditions [66, 67].
Histone acetylation is a reversible modification con-
trolled by enzymes that add (histone acetyltransferases
(HATs)) or remove (histone deacetylases (HDACs)) acetyl
groups from specific lysine residues in the various histones.
The importance of histone acetylation was demonstrated by
inhibiting HDAC3, a histone H4 deacetylase. Treatment of
parasites with a HDAC3 inhibitor (FR235222) induced
tachyzoite to bradyzoite differentiation. DNA complexes
co-immunoprecipitated using α-acetyl-H4 antibodies and
hybridized to a high-resolution Toxoplasma DNA micro-
array demonstrated that the promoters of many but not all
bradyzoite genes were hyper-acetylated on histone H4 [68].
But the fact that not all bradyzoite-specific genes harbored
this modification suggests that other histone modifications
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may be important for regulating these genes. Altogether,
these data paint a picture in which differentiation is
controlled transcriptionally by both DNA binding proteins
and by epigenetic-based histone modifications. But how all
of these changes come together to convert a tachyzoite to a
bradyzoite remains unclear.
Besides epigenetic control of Toxoplasma gene expres-
sion during bradyzoite differentiation, HATs are expressed
in tachyzoites [69, 70] and the expression of some
tachyzoite-specific genes are epigenetically regulated [67,
71]. An extremely high-resolution DNA oligonucleotide
Toxoplasma microarray representing a well-annotated
region of Chromosome Ib was used in CHIP-on-chip
assays to characterize the organization of active and silent
promoters in tachyzoites [72]. This study demonstrated that
the location and organization of specific modifications of
acetylated and methylated histones within the genome
could predict not only whether a promoter was active but
the 5′–3′ orientation of the gene it was regulating.
As an intracellular pathogen, the interplay between the
parasite and host cell is likely to have an impact on all
aspects of the parasite life cycle including bradyzoite
development. An example of this interplay came from the
observation that a novel drug named Compound 1
stimulated bradyzoite development in specific Toxoplasma
strains [73]. Multifactorial microarray analysis of RNA
isolated from Compound-1-treated, mock-infected, or
parasite-infected host cells led to the discovery that over-
expression of a human gene named CDA1 was sufficient to
promote bradyzoite development. CDA1 encodes a protein
whose overexpression leads to cell cycle arrest suggesting
the status of the host’s cell cycle determines if a parasite
will undergo bradyzoite development. This is an intriguing
hypothesis given the observations that bradyzoites appear
to preferentially develop in cells such as neurons and
muscle cells that have exited from the cell cycle [74–76].
Virulence
The population structure of Toxoplasma is extremely clonal
and the genotypes of the majority of Toxoplasma strains
isolated in North America and Europe group into one of
three clonal lineages (types I, II, and III) [77, 78]. In mice,
type I strains are highly virulent while the other two are
significantly less so [79]. Although all Toxoplasma strain
types can cause disease in human infections, type II strains
are more commonly associated with congenital infections
and toxoplasmic encephalitis while type I and other atypical
strains are more commonly associated with postnatally
acquired infections that lead to ocular disease [80, 81].
Understanding the basis for differences between Toxoplasma
strain types is important for two reasons. First, optimal
treatment options to either prevent or cure reactivated
infections may be dictated by the parasite’s genotype.
Second, optimal vaccine design necessitates identifying
non-polymorphic antigens.
Toxoplasma virulence is a multi-step, complicated
process comprised of transmission, dissemination, host
immune evasion, encystation, and reactivation. Although
it was commonly accepted that multiple parasite genes
would be important for virulence, the first experimental
data that this was true came from the finding that a cross
between either two avirulent genotypes (types II and III)
resulted in virulent progeny [82]. Quantitative trait locus
(QTL) mapping of these progeny identified five virulence
loci [83]. Thus far, two of these virulence genes have been
identified as ROP16 and ROP18. These virulence genes
encode rhoptry kinases that are secreted into infected host
cells. In an independent study, QTL mapping of progeny
from a type I/III cross also identified ROP18 as a virulence
gene [84].
One way that the different strains may affect virulence is
by differentially modulating host gene expression [12].
Based on human DNA microarray analysis, over 3,000 host
genes were differentially expressed in cells infected with
progeny from the type II/III cross [12]. Expression QTL
mapping of these differences in host gene expression
indicated that at least one locus on each parasite chromo-
some is responsible for differential expression of a portion of
these host genes. Modulation of the largest number of these
genes (~1,100 genes) mapped to a single locus on
Chromosome VIIb and ROP16 was determined to be the
gene responsible for these differences in host gene expres-
sion. Pathway analysis indicated that many ROP16-
modulated genes were targets of the STAT3/STAT6 tran-
scription factors. How ROP16 specifically regulates STAT3/
STAT6-dependent expression is unknown but infection with
parasites harboring the type III allele of ROP16 (which is
identical to the allele in type I strains) leads to sustained
activation of STAT3/STAT6 [12]. Given ROP16’s role in
virulence it is therefore tempting to speculate that sustained
STAT3/STAT6 activation causes an overproduction of pro-
inflammatory cytokines that can induces immune-mediated
tissue destruction.
NK and T-cell-derived IFNγ is the critical cytokine in
protection against infections with all Toxoplasma strains
[85]. This cytokine protects against Toxoplasma infections
by upregulating the expression of inducible nitric oxide
synthase, indoleamine dioxygenase, and a family of IFNγ-
regulated GTPases that degrade the parasitophorous vacuole
(reviewed in [86]). Regardless of its effectiveness, some
parasites can evade IFNγ-mediated killing and develop into
bradyzoites. One possible mechanism by which the parasite
avoids IFNγ is to disable IFNγ-induced signaling. Indeed,
microarray and cell biological assays demonstrated that
IFNγ-induced transcription is abrogated in cells previously
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infected with Toxoplasma [87, 88]. In contrast to the
polymorphic ROP16 and ROP18 virulence factors, Toxo-
plasma’s effects on IFNγ-dependent transcription are strain
independent [87]. The mechanism underlying parasite
abrogation of IFNγ-stimulated transcription is still unclear
but does not appear to involve blocking nuclear localization
of STAT1, which is a key IFNγ-regulated transcription
factor. However, infection upregulates the expression of
members of the suppressor of cytokine signaling (SOCS)
family that function by preventing sustained STAT1 activa-
tion or levels [89]. Thus, the parasite may utilize a feedback
regulatory mechanism to reduce IFNγ-dependent signaling.
It should be noted that others have failed to find evidence of
SOCS-mediated inhibition of IFNγ signaling since they did
not detect differences in STAT1 protein levels in mock- or
parasite-infected cells [87, 90]. Instead, these studies suggest
that the parasite affects the ability for STAT1 to bind DNA.
Implications for ocular toxoplasmosis
It is critical that the retina be protected from inflammation-
induced damaged because photoreceptors and other neuro-
retinal cells cannot be replaced or regenerated. One way
the retina does this is by maintaining its immune-
privileged state that is characterized by a lack of
lymphatics, few endogenous antigen-presenting cells, and
the blood-retinal barrier [91]. Regardless, retinal infec-
tions do occur and proper regulated protective immune
responses are necessary.
Toxoplasma is one of the most common infections of the
retina and normally resides in quiescent tissue cysts. Two
lines of evidence indicate that in the retina Toxoplasma
cysts occasionally reactivate (reviewed in [92]). First,
parasite-induced retinal scarring is often observed in
Toxoplasma-infected individuals. In many cases, active
lesions lie adjacent to older ones and are noted as satellite
scars. This satellite scarring is caused by the short migration
of some parasites after they emerge from a reactivated cyst.
These migrated parasites then re-encyst and the new lesion
begins after this cyst reactivates. Second, immune suppres-
sion of a chronically infected animal leads to ocular
toxoplasmosis. Together, these data indicate that Toxoplas-
ma tissue cysts are normally found in the retina, they
sporadically reactivate, and efficient immune responses are
required to limit parasite growth and stimulate them to re-
encyst.
CD8 T cells, and to a lesser extent CD4 T cells and B
cells, are required for protection against Toxoplasma in the
peripheral tissues and the retina [93–95]. In addition, the
early recruitment of blood-derived monocytes and neutro-
phils is also critical for protection [96, 97]. Thus, a key
question is what signals the recruitment of these cells to the
infected retina. DNA microarray analysis of several types
of parasite-infected retinal cells (Müller and endothelial
cells) [98, 99] demonstrated that several chemokines,
whose primary function are the recruitment of immune
cells, were upregulated by infection. These chemokines
included those that recruit neutrophils—(CXCL1 (GROα),
CXCL2 (GROβ), CXCL8 (IL-8), and CXCL6 (GCP2));
monocytes—CCL2 (MCP1), CCL5 (RANTES), and
CX3CL1 (fractalkine); and T cells—CXCL10 (IP10) and
CXCL11 (I-TAC). These data are consistent with the
finding that neutrophils, monocytes, and T cells are the
major types of leukocytes present in Toxoplasma-infected
retinas (E. Charles and I. J. Blader, manuscript in
preparation). These data are also largely consistent with
the responses of other types of Toxoplasma-infected host
cells suggesting that parasite-induced chemokine expres-
sion is largely independent of the type of infected host cell
or tissue.
While these experiments have helped shed light on what
directs immune cells to parasite-infected retinas, they still
leave many questions unanswered. First, how are reacti-
vated infections recognized in the retina? In the periphery,
various TLR receptors (e.g. TLR2, TLR4, and TLR11)
recognize Toxoplasma-derived factors [100–102]. But
whether specific TLRs or other pattern recognition mole-
cules are required in the retina is unclear [103]. While it is
established that toll receptors are expressed in the retina it is
not known how they contribute to the mobilization of a
memory T-cell-based retinal immune response [104, 105].
Second, which antigen presenting cells are responsible for
activation of memory CD8+ and CD4+ T cells? This is a
particularly interesting problem for the retina since the
existence of professional antigen-presenting cells in the
retina has not been formally established. Thus, does
infection induce a resident retinal cell (e.g. retinal microglia
or astrocyte) to develop these properties or is antigen
presentation a function only fulfilled by an infiltrating
leukocyte? Third, which type of memory (effector vs.
central) T cell is activated during a reactivated retinal
infection? Finally, do the T cells that gain access to the
infected retina do so because of a breach in blood–retinal
barrier integrity or because the retina selectively permits
specific types of T cells to gain entry? Obviously, these
issues are not unique to ocular toxoplasmosis but are also
relevant to other types of infection of the retina and other
immune-privileged tissues. But given the experimental
manipulability of Toxoplasma, it is likely that important
progress will soon be made.
In addition to the immunological aspects of ocular
toxoplasmosis, more parasite-centric questions regarding
ocular toxoplasmosis need to be addressed and DNA
microarrays are poised to have an important role in
addressing them. For example, what parasite virulence
factors act in the retina? As discussed above, ROP16 and
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ROP18 were identified as virulence factors using QTL-
based approaches. But, how these two proteins function is
not known nor is it clear whether they would have a role in
the retina. Besides these two proteins, the SAG1 parasite
surface protein was proposed to have an important role in
Toxoplasma-induced intestinal damage and loss of SAG1
had a slight effect on subsequent retinal damage after
parasites were injected into the anterior chamber of the eye
[106, 107]. But, when parasites were directly injected into
the posterior chamber, there were no apparent differences in
retinal damage between wild-type and SAG1 knockout
parasites [108]. These data suggested that SAG1 was not
acting as a virulence factor per se in the retina but rather
may help the parasite cross anatomical barriers (e.g. traffic
from the anterior to posterior chambers).
Another question that has not been addressed is how
parasite gene expression is influenced by the host cell it is
growing within. This could be important since different
host cells present different environments and challenges
that the parasite must overcome. For example, macrophages
may release higher levels and be more responsive to anti-
toxoplasmotic host defense molecules such as oxygen
radicals, IFNγ, and TNFα. To survive in these conditions,
parasites have developed several strategies. For example,
they express an efficient set of antioxidant proteins that
protect the parasite from oxidative damage [109]. But the
parasite also express novel stress response/immune evasion
factors as was demonstrated by the discovery that a novel
parasite protein containing a patatin-like phospholipase
domain was required for survival in activated macrophages
[110]. It is likely that additional stress response/immune
evasion factors remain to be discovered. As they have in
bacterial and fungal pathogens, DNA microarrays are
poised to have an important role in the identification of
these factors and the proteins they interact with [111, 112].
As a parasite with a potentially devastating clinical
outcome, an important goal of ocular toxoplasmosis
research is the development of new drugs and treatments.
There are two major reasons that new drugs are needed to
treat Toxoplasma infections. First, the drugs currently
used to treat Toxoplasma infections are poorly tolerated,
have severe side effects, and cannot act against brady-
zoites [113, 114]. Second, there are reports that Toxo-
plasma is developing resistance to the current generation
of drugs [115, 116]. How resistance to these drugs has
developed is not known but is critical to understand
because it will lead to improved drug design and will
increase our understanding of the biological functions of
these drug targets. One way to understanding mechanisms
of resistance is to compare the transcriptional profiles of
wild-type and resistant parasites grown in the absence or
presence of the drug. Such studies in bacterial resistance
have demonstrated that pathogen responses to antibiotics
are multifactorial and complex [117]. Whether the same
will be true in Toxoplasma is unclear, but data from these
types of experiments will likely impact new anti-Toxoplasma
drug design.
Ocular toxoplasmosis is more severe and prevalent in
Brazil than in Europe or North America suggesting that
either parasite strains or host responses are responsible for
these differences [118]. Genotyping of strains from the
Brazilian patients have identified parasite strains that are
highly divergent from the types I, II, and III strains found in
Europe and North America [119]. But what properties of
these strains confer their ability to cause severe ocular
disease is not known. Given the significantly reduced costs
of whole genome sequencing, it is likely that genome
sequences of these novel strains will provide important
clues. But, these studies will need to be followed by others
that examine the transcriptome and proteome of these
strains in order to understand how these changes in
sequence correspond to biologically distinct phenotypes.
Summary
Over the past decade, the application of host and parasite
microarrays have allowed Toxoplasma researchers to make
great strides in understanding how Toxoplasma grows,
differentiates, and causes disease. The majority of these
experiments have thus far focused on tissue culture-based
experimental systems or death-as-endpoint virulence stud-
ies. Relative to these systems, our understanding of how
Toxoplasma interacts with and causes disease in the retina
has been lagging. But the techniques and technologies that
these other studies have pioneered (e.g. microarrays, QTL
screening, and epigenetic mapping) coupled with high-
throughput DNA sequencing and proteomics, will allow
ocular toxoplasmosis researchers to make important and
rapid advances in the very near future.
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